Navigation Links
PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
Date:3/19/2009

ANNAPOLIS, Md., March 19 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2008 will be released on Monday, March 30, 2009.

PharmAthene management will be hosting a conference call to discuss its year end financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Monday, March 30, 2009 and will last approximately 45 minutes.

The dial-in number within the United States is 866-383-8003. The dial-in number for international callers is 617-597-5330. The participant passcode is 25699583.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. Eastern Time on Monday, March 30, 2009 until approximately 11:59 p.m. Eastern Time on April 30, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 35301584.

The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found on both under the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valort
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire-USNewswi...entists, policy makers, and funders today convened...ative funding strategies at the inaugural Partner...Washington-based center of the Milken Institute, c...-sector collaborations needed to turn a scientific...
(Date:12/2/2009)..., , LELYSTAD, The Netherlands, Decemb...rlands based biotechnology company focusing on pro...mune therapeutics today announced that it,has appo...fficer. , Dr. Mol will be responsible for...ll management and strategic direction of the compa...
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...nnounced that 105 of,its drugs have been included ..."), which was issued by China,s Ministry of Human ...
(Date:12/1/2009)... Dr. Kerry Solomon announ... and has launched his redesigned website at www.D... Consulting Group. Dr. Solomon is a proven LASIK,... been professionally recognized for his substantia...gery. He is a member of Trusted LASIK Surgeons, w...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...USALEM and NEEDHAM, Massachusetts, December 10 /PR...wiss Exchange: ORIDN) today announced that,three s...be presented at the,upcoming AARC (American Associ...alifornia. These studies confirm the clinical bene...dion Microstream(R) capnography technology,and cle...
...SANNE, Switzerland, December 10 Diagnoplex, a,dev...nced the closing of a,Series A financing raising C...y Novartis Venture Fund and NeoMed, with Initiativ...rtis Venture Fund was also a seed investor in the,...stors and BMP Associés,acted as counsel to the co...
...MOUTH, Minn., Dec. 9 ev3 Inc. (Nasdaq: EVVV ),a...ay that it has received,510(k) clearance from the ...t its,EverCross 0.035" and NanoCross 0.014" periph...o begin full commercialization of the EverCross an...in January 2009. , Robert Palmisano, ev3,s presi...
Other Biology Technology:Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing 2Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing 3ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 2ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 3
(Date:12/2/2009)...tudy results strengthen the evidence that people w...e an increased risk for developing colorectal canc..., "This provides one more reason not to smoke, o... Michael J. Thun, M.D., M.S., vice president emeri... American Cancer Society. "Colorectal cancer shoul...
(Date:12/2/2009)...ce of a cancer-free status did not prompt people p...y (CT) lung-cancer screening program to pick up th... published in Cancer Epidemiology, Biomarkers & P...for Cancer Research. The December issue contains a...ld negate widespread concern in the lung screening...
(Date:12/2/2009)...iversity Medical Center researchers have figured o...ioma may be better able to resist radiation therap...g pathway in these cancer stem cells, they were ab...n a laboratory experiment. , The work builds of...ells resist the effects of radiation much better t...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Discovery makes brain tumor cells more responsive to radiation 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 1Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 3Silenced genes as a warning sign of blood cancer 53655 1Silenced genes as a warning sign of blood cancer 53655 2Nanotechnology Transforms Pain Relief 53652 1Nanotechnology Transforms Pain Relief 53652 2Nanotechnology Transforms Pain Relief 53652 3Nanotechnology Transforms Pain Relief 53652 4
...om The Wistar Institute in Philadelphia and The Vi...mechanism involved in normal repression of the p53...le for the control of cancer in humans. , The new... intriguing approaches to diagnosing or intervenin...port on the team,s findings will be published onli...
...ervational study by researchers at the University ...n between 65 and 80 years of age who received trea...ived significantly longer than men who did not rec... December 13th issue of the Journal of the America...revention education and the resulting wide-spread ...
...mazing protein-making parts out of cells and putti...eins for a wide variety of medical uses. At the an...) Sept. 13 in San Francisco, Stanford engineering ...ch "cell-free" protein synthesis, including produc...n act as delivery trucks for a new class of potent...
Other Biology News:Novel regulatory mechanism identified for key tumor suppressor p53 2Novel regulatory mechanism identified for key tumor suppressor p53 3Older men treated for early prostate cancer live longer than those who are not 2Engineer ramps up protein production, develops versatile viral spheres 2Engineer ramps up protein production, develops versatile viral spheres 3
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Glutathione Agarose Beads from BD Biosciences Pharmingen
Biology Products: